A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease

摘要

Introduction Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events.